Rat igg2b

Manufactured by BioXCell

Sourced in United States

Rat IgG2b is an immunoglobulin subclass produced by rats. It is a laboratory reagent used for various research applications.

Automatically generated - may contain errors

Lab products found in correlation

Rat igg2a, by BioXCell (5 mentions) Rat igg1, by BioXCell (4 mentions) Diphtheria toxin, by Merck Group (3 mentions) Ltf 2, by BioXCell (2 mentions) Mouse igg1, by BioXCell (2 mentions) Bleomycin, by Thermo Fisher Scientific (2 mentions) Bleomycin, by BioXCell (2 mentions) Bleomycin, by Merck Group (2 mentions) Anti pd l1, by BioXCell (2 mentions) Clone 53 6, by BioXCell (1 mentions) Cd4 brilliant violet 785, by BioLegend (1 mentions) Cd8 fitc, by BioLegend (1 mentions) Clone gk1, by BioXCell (1 mentions) Zombie aqua, by BioLegend (1 mentions) Fc block, by BD (1 mentions) Easysep cd8 t cell isolation kit, by STEMCELL (1 mentions) Mopc 1, by BioXCell (1 mentions) Cyclophosphamide ctx, by Merck Group (1 mentions) Rb6 8c5, by BioXCell (1 mentions) Gk1.5 antibody, by BioXCell (1 mentions)

Close spelling variants of this product

Rat IgG2b isotype control (28 citations) IgG2b (19 citations) Rat IgG2b (clone LTF-2, (19 citations) Rat IgG2b isotype control (clone LTF-2, (17 citations) Rat IgG2b (LTF-2; (8 citations) InVivoMAb rat IgG2b isotype control (8 citations) Rat IgG2b isotype control (LTF-2; (6 citations) Anti-CD4 (rat IgG2b clone GK1.5, (4 citations) Rat IgG2b isotype control antibody (4 citations) Rat IgG2b anti-KLH (3 citations)

38 protocols using rat igg2b

In vivo T-cell depletion and serum transfer

Check if the same lab product or an alternative is used in the 5 most similar protocols

CD4 or CD8 T-cell subsets were depleted in BALB/c mice by intraperitoneal injection of 250 µg of anti-CD4 (rat IgG2b, Clone GK1.5, Bio X Cell) or anti-CD8 (rat IgG2b, Clone 53-6.7, Bio X Cell) antibody 1 day before and 1 day after challenge. As control, an isotype-matched antibody (rat IgG2b, LTF-2, Bio X Cell) was used. For long-term depletion of CD4 T cells, injection was performed 2 days before prime vaccination and twice a week thereafter. At Day 39 (4 days post RSV-A2 challenge), the efficacy of these treatments was determined by FACS analysis of heparinized whole blood and splenocytes. Briefly, cells were treated with a purified anti-mouse CD16/CD32 monoclonal antibody (1:50, Fc Block™, BD) prior to staining with CD8 FITC (1:200; BioLegend) and CD4 brilliant violet 785 (1:200, BioLegend). For live versus dead cell discrimination, Zombie Aqua™ (1:200, BioLegend) was used. All cells were acquired using a digital flow cytometer (LSR II, BD Biosciences), and data were analyzed with FlowJo software (Tree Star).
Serum from MVA-RSV-vaccinated or mock-treated control mice was transferred by intraperitoneal (IP) injection of 1 ml of serum to non-vaccinated BALB/c mice 1 day before challenge.

Endt K., Wollmann Y., Haug J., Bernig C., Feigl M., Heiseke A., Kalla M., Hochrein H., Suter M., Chaplin P, & Volkmann A. (2022). A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection. Frontiers in Immunology, 13, 841471.

+ Open protocol

+ Expand

Antibody characterization and in vivo use

Check if the same lab product or an alternative is used in the 5 most similar protocols

The 314.8 mAb (mouse IgG1 anti-human ICOS) has been described before.²¹ Isotype controls (mouse IgG1, MOPC-1; rat IgG2b, LTF-2) and anti-Gr1 mAb (rat IgG2b, RB6-8C5) were purchased from BioXcell (West Lebanon, NH, USA). The MT807R1 recombinant Ig consisting of rhesus IgG1k constant regions and CDRs derived from the anti-human CD8 antibody M-T807 grafted into rhesus variable framework regions and was provided by the Nonhuman Primate Reagent Resource (NIH contract HHSN272200900037C and grant RR016001). The antibody was expressed in vitro using serum-free medium and purified by protein-A affinity chromatography. Endotoxin was <1EU/mg. Cyclophosphamide (CTX, Sigma Aldrich) was prepared extemporaneously according to supplier technical data sheet, i.e to 20 mg/ml of injectable water. All reagents were injected intraperitoneally.

Burlion A., Ramos R.N., KC P., Sendeyo K., Corneau A., Ménétrier-Caux C., Piaggio E., Olive D., Caux C, & Marodon G. (2019). A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system. Oncoimmunology, 8(7), 1596005.

+ Open protocol

+ Expand

ZIKV Infection Model with CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Four- to 5-week-old male and female HLA-B*0702 Ifnar1^−/− mice were vaccinated and boosted with NS3 vaccine or saline as described above. Spleens were harvested on day 49, and CD8⁺ T cells were purified from the spleens by negative selection using the EasySep CD8+ T Cell Isolation Kit (StemCell). Purified CD8⁺ T cells (10⁷ per mouse) were intravenously injected into 7- to 8-week-old HLA-B*0702 Ifnar1^−/− recipient mice. One day later, the recipient mice were infected retro-orbitally with ZIKV SD001. For the depletion experiments, vaccinated and boosted mice were intravenously injected with 300 μg of a CD8-depleting monoclonal antibody (mAb) (2.43, Bio X Cell) or an isotype control mAb (rat IgG2b, Bio X Cell) on days −3 and −1 before infection retro-orbitally with ZIKV SD001. In both sets of experiments, blood and organs were harvested 3 days later and ZIKV RNA was quantified.

Elong Ngono A., Syed T., Nguyen A.V., Regla-Nava J.A., Susantono M., Spasova D., Aguilar A., West M., Sparks J., Gonzalez A., Branche E., DeHart J.L., Vega J.B., Karmali P.P., Chivukula P., Kamrud K., Aliahmad P., Wang N, & Shresta S. (2020). CD8+ T cells mediate protection against Zika virus induced by an NS3-based vaccine. Science Advances, 6(45), eabb2154.

+ Open protocol

+ Expand

PD-1/PD-L1 Blockade and CD4+ T Cell Depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols

CD4 T cell depletions were performed by injection of 500 μg of GK1.5 antibody (BioXcell) 2 days and again 1 day prior to PD-1/PD-L1 blockade. PD-L1 blockade was achieved by injection of 200 μg of 10F.9G2 (BioXcell) at different times throughout the course of lifelong infection, and the regimen consisted of five doses every three days as previously described(9 (link)). All antibody treatments were given intraperitoneally (diluted in DPBS). Rat IgG2b (BioXcell) was used as negative control. CD8 T cell rescue and antiviral control were assessed at day 15 post-treatment.

Penaloza-MacMaster P., Provine N.M., Blass E, & Barouch D.H. (2015). CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. The Journal of Immunology Author Choice, 195(3), 1054-1063.

+ Open protocol

+ Expand

Modulating Immunity in Ischemic Injury

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were injected i.p. with 300 μg isotype control or blocking antibodies purchased from BioXCell (West Lebanon, NH): rat IgG2a (clone: 2A3) – control for anti-PD-L2, rat IgG2b (clone: LTF-2) – control for anti-PD-L1, rat anti-PD-L1 (clone: 10F.9G2), rat anti-PD-L2 (clone: TY25). The antibodies were administered to the mice 24 h prior to IRI. Tregs were isolated from spleen of naïve WT mice with Dynal (Carlsbad, CA) CD4 negative selection kit and Miltenyi Biotec (Auburn, CA) CD25 positive selection kit according to the manufacturers’ protocols as previously described (18 (link)–20 (link)). One hundred thousand freshly isolated Tregs (in 200 microliters of normal saline) were administered to the mice 18 h prior to IRI (6 hours after injection of isotype or blocking antibodies).

Jaworska K., Ratajczak J., Huang L., Whalen K., Yang M., Stevens B.K, & Kinsey G.R. (2014). Both PD-1 ligands protect the kidney from ischemia reperfusion injury. Journal of immunology (Baltimore, Md. : 1950), 194(1), 325-333.

+ Open protocol

+ Expand

Monoclonal Antibodies for Immune Cell Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

For injections, purified monoclonal anti-mouse IFNAR1 (MAR1–5A3), isotype mouse IgG1 and rat IgG2b were obtained from BioXCell, and purified monoclonal anti-mouse BST2/CD317 antibody (JF05–1C2.4.1) was obtained from Miltenyi Biotec. For flow cytometric staining, fluorescence conjugated anti-CD45 (30-F11), anti-CD4 (GK-1.5), anti-CD8 (53–5.8), anti-B220 (RA3–6B2), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD86 (GL-1), anti-BST2/CD317, anti-CD11b (M1/70), anti-CD11c (N418), anti-Siglec-H (clone 551) and anti-CD16/32 antibodies were all purchased from BioLegend. For immunohistochemical staining, rat anti-BST2/CD317 antibody (clone 927) was obtained from BioXCell, and biotin conjugated anti-rat IgG was purchased from Vector Laboratories. For immunofluorescence staining, Alexa Fluor568-conjugated anti-mouse IgG was purchased from Abcam.

Zhou J., Zhang X, & Yu Q. (2021). Plasmacytoid dendritic cells promote the pathogenesis of Sjögren’s syndrome. Biochimica et biophysica acta. Molecular basis of disease, 1868(2), 166302.

+ Open protocol

+ Expand

Modulating Tumor Immunity via CTLA4 and PD-L1

Check if the same lab product or an alternative is used in the 5 most similar protocols

8- to 12-week-old female mice were injected subcutaneously with 100μl PBS containing 5×10⁵ B16ova melanoma cells into the left, ventral flank. Intraperitoneal injection of 200μl PBS containing either 0.4mg of a Syrian hamster anti-mouse CTLA4 (Clone UC10-4F10-11; BE0131), 0.5mg rat anti-mouse PD-L1 (Clone10F.9G2; BE0101), 0.4mg Syrian hamster IgG (BE0087) or 0.5mg rat IgG2b (Clone LTF-2; BE0090) (all from BioXCell, USA) was performed every 3 days starting from day 0 of B16ova challenge until day 18.
Tumor volume was calculated according to the following equation: V = π/6*length*width². For survival analysis, mice with tumors exceeding the length limit of 15 mm were sacrificed and counted as dead.

Peer S., Baier G, & Gruber T. (2017). Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition. Oncotarget, 8(26), 41841-41853.

+ Open protocol

+ Expand

In Vivo Macrophage Depletion Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were injected by I.P. injection with anti‐CSF‐1R (CD115) antibody (AFS98, Bio X Cell, West Lebanon, NH) or anti‐CD11b antibody (M1/70, Bio X Cell,) at a dose of 5 mg kg⁻¹ body weight (in 300 µL dilution buffer, in vitro pure, pH = 7.4) 24 h before glycolipid administration. For the control group, the same amount of rat IgG2b (Bio X Cell) was administered. To characterize the efficacy of monocyte/macrophage depletion in vivo, mice were I.V. injected with clodronate liposomes (from Vrije University Amsterdam) at 5 mg kg⁻¹ body weight in 200 µL PBS 48 h before glycolipid administration. For the control group, an equal amount of control PBS‐laden liposomes was administered. All liposomes were purchased from YEASEN Inc., Shanghai, China.

Ma J., He P., Zhao C., Ren Q., Dong Z., Qiu J., Jing Y., Liu S, & Du Y. (2020). A Designed α‐GalCer Analog Promotes Considerable Th1 Cytokine Response by Activating the CD1d‐iNKT Axis and CD11b‐Positive Monocytes/Macrophages. Advanced Science, 7(14), 2000609.

+ Open protocol

+ Expand

CD8+ T Cell Depletion and Macrophage Modulation in Tumor Models

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

For CD8⁺ T cell depletion, 200 μg anti-mouse CD8α antibody (clone 2.43, BioXcell) or isotype control (rat IgG2b, BioXcell) was intraperitoneally (i.p.) injected into mice every three days four times in the presence or absence of BF10 cotreatment. The depletion efficacy of CD8 T cells was examined by flow cytometry analysis of mouse peripheral blood samples (pre-bleed and post-bleed) and IHC as indicated. The macrophage depletion was accomplished by intraperitoneal administration of clodronate-Liposome (Liposoma BV, Netherlands) as our previous study.³ (link) Briefly, Tumor-bearing mice were received with clodronate- and/or PBS- liposome solution (200μL contains 1mg clodronate for 20g mice) at the indicated time, followed by co-treatment of IL-10-Fc or BF10 with a three-day interval for tumor growth analysis.

Chang Y.W., Hsiao H.W., Chen J.P., Tzeng S.F., Tsai C.H., Wu C.Y., Hsieh H.H., Carmona S.J., Andreatta M., Di Conza G., Su M.T., Koni P.A., Ho P.C., Chen H.K, & Yang M.H. (2023). A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8+ T cells. Cell Reports Medicine, 4(8), 101154.

+ Open protocol

+ Expand

Anti-PD-L1 Immunotherapy in Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols

In the subcutaneous tumor-bearing model, 10⁷ ATT-20/D16v.2 cells were injected subcutaneously into the left flank of LAF1 mice on day 0. Following tumor implantation, mice were treated intraperitoneally (ip) with 200 μg of either anti–PD-L1 (clone 10F.9G2; BioXCell) or isotype control antibody (Rat IgG2b; BioXCell) every 3 days starting on day 3 for 12 total doses until day 36. In our intracranial tumor-bearing model, 5 × 10⁴ D16v.2 cells were injected intracranially at day 0. Beginning on day 3, mice were treated intraperitoneally with either 200 μg of anti–PD-L1 (10F.9G2; BioXCell) or PBS (Gibco Thermo Fisher Scientific) control every 3 days starting on day 3 for 15 total doses until day 45.

Kemeny H.R., Elsamadicy A.A., Farber S.H., Champion C.D., Lorrey S.J., Chongsathidkiet P., Woroniecka K.I., Cui X., Shen S.H., Rhodin K.E., Tsvankin V., Everitt J., Sanchez-Perez L., Healy P., McLendon R.E., Codd P.J., Dunn I.F, & Fecci P.E. (2019). Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 1141-1151.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!